On January 20, 2023, BioCorRx Inc. (the “Company”) appointed Harsha Murthy as a member of the Board of Directors (the “Board”) of the Company (the “Murthy Appointment”). The Company and Mr. Murthy entered in a Director Agreement, dated January 20, 2023 (the “Murthy Director Agreement”). Pursuant to the Murthy Director Agreement, Mr. Murthy shall make reasonable business efforts to attend all Board meetings, serve on appropriate subcommittees as reasonably requested by the Board, make himself available to the Company at mutually convenient times and places, attend external meetings and presentations, as appropriate and convenient, and perform such duties, services and responsibilities, and have the authority commensurate to such position.

Mr. Murthy will receive a quarterly cash stipend of $15,000. For so long as Mr. Murthy serves as the chair of either the Audit Committee of the Board, the Compensation Committee of the Board or the Nominating Committee of the Board, the amount of such quarterly cash stipend may be increased from time to time. Mr. Murthy will also be issued, upon the last day of each fiscal quarter, commencing in the quarter in which he enters into the Murthy Director Agreement, provided he is a member of the Board as of such date, the number of shares of the Company's common stock equivalent to $5,000 as determined based on the average closing price on the three trading days immediately preceding the last day of such quarter.